### Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype

2 SARS-CoV-2 specific T cells

1

3

6

- Catherine Riou<sup>1,2,\*</sup>, Georgia Schäfer<sup>1,3,4</sup>, Elsa du Bruyn<sup>1,5</sup>, Rene T. Goliath<sup>1</sup>, Cari Stek<sup>1,5,6</sup>, Huihui 4
- Mou<sup>7</sup>, Deli Hung<sup>8</sup>, Katalin A. Wilkinson<sup>1,5,9</sup>, Robert J. Wilkinson<sup>1,5,6,9</sup> 5
- 7 <sup>1</sup> Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease
- and Molecular Medicine, University of Cape Town, Observatory 7925, South Africa 8
- 9 <sup>2</sup> Division of Immunology, Department of Pathology, University of Cape Town, Observatory
- 10 7925, South Africa
- <sup>3</sup> International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town, 11
- 12 Observatory 7925, South Africa
- <sup>4</sup> Division of Medical Biochemistry and Structural Biology, Department of Integrative 13
- Biomedical Sciences, University of Cape Town, Observatory 7925, South Africa 14
- 15 <sup>5</sup> Department of Medicine, University of Cape Town, Observatory 7925, South Africa
- <sup>6</sup> Department of Infectious Diseases, Imperial College London, W12 0NN, UK 16
- <sup>7</sup> Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL 17
- 33458, USA 18
- 19 <sup>8</sup> Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA
- 20 92037, USA

22

25

27

29

- 21 <sup>9</sup> The Francis Crick Institute, London, NW1 1AT, UK
- 23 \* Corresponding Author: Catherine Riou, University of Cape Town, IDM, Anzio Road,
- Observatory, 7925, Cape Town, South Africa. E-mail: cr.riou@uct.ac.za 24
- 26 **Key words:** COVID-19, T cells, Whole blood Assay
- 28 Running title: SARS-CoV-2-specific whole blood T cell assay.
- 30 **40-word summary:** In this proof of concept study, we show that SARS-CoV-2 T cell responses
- 31 are easily detectable using a rapid whole blood assay requiring minimal blood volume. Such
- assay could represent a suitable tool to monitor adaptive immunity in vaccine trials. 32

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

**ABSTRACT** 

vaccine trials.

Rapid tests to evaluate SARS-CoV-2-specific T cell responses are urgently needed to decipher protective immunity and aid monitoring vaccine-induced immunity. Using a rapid whole blood assay requiring minimal amount of blood, we measured qualitatively and quantitatively SARS-CoV-2-specific CD4 T cell responses in 31 healthcare workers, using flow cytometry. 100% of COVID-19 convalescent participants displayed a detectable SARS-CoV-2-specific CD4 T cell response. SARS-CoV-2-responding cells were also detected in 40.9% of participants with no COVID-19-associated symptoms or who tested PCR negative. Phenotypic assessment indicated that, in COVID-19 convalescent participants, SARS-CoV-2 CD4 responses displayed an early differentiated memory phenotype with limited capacity to produce IFN $\gamma$ . Conversely, in participants with no reported symptoms, SARS-CoV-2 CD4 responses were enriched in late differentiated cells, co-expressing IFN $\gamma$  and TNF $\alpha$  and also Granzyme B. This proof of concept study presents a scalable alternative to PBMC-based assays to enumerate and phenotype SARS-CoV-2-responding T cells, thus representing a practical tool to monitor adaptive immunity in

INTRODUCTION

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

The outbreak of SARS-CoV-2 infection (causing the disease known as COVID-19) that first emerged in Wuhan. China in December 2019, was declared a global pandemic on 12<sup>th</sup> March 2020, and is affecting all countries of the world, including those of Africa (Margolin et al., 2020). There is an urgent need to understand better the clinical manifestations and the pathogenesis of SARS-CoV-2 in order to develop relevant tools, including diagnostic tests, treatments and vaccines, to stop the spread of disease as well as strategies to best manage this disease in all population groups. The clinical spectrum of COVID-19 is very wide, from asymptomatic through mild flu-like symptoms to severe pneumonia and death. Understanding what constitutes immune protection against SARS-CoV-2 is key to predicting long-term immunity and to inform vaccine design. While much emphasis has been placed on the B cell and antibody response, it is not yet clear what type of immune response confers protection to SARS-CoV-2 (Cox and Brokstad, 2020). Several studies suggest that the T cell response may play an important role in SARS-CoV-2 pathogenesis and reports indicating that patients lacking B cells can recover from SARS-CoV-2 infection further highlight the likely importance of T cell immunity (Altmann and Boyton, 2020); (Quinti et al., 2020). Additionally, accumulating evidence indicates that the presence of preexisting, cross-reactive memory T cells specific for common cold coronaviruses may affect susceptibility to SARS-CoV-2 infection and partially explain the markedly divergent clinical manifestations of COVID-19 (Braun et al., 2020; Canete and Vinuesa, 2020; Lipsitch et al., 2020; Sette and Crotty, 2020). Efficient, sensitive and simple assessment of human T-cell immunity remains a challenge. Most commonly used T cell assays necessitate the isolation of peripheral blood mononuclear cells

(PBMC), requiring significant amount of blood. Therefore, whole blood assays could be more advantageous than PBMC-based methods, by significantly reducing blood volume (~ 1 ml), making them more applicable to paediatric populations. Moreover, such assays are rapid, as they don't require cell separation, and preserve the physiologic cellular and soluble environments, mimicking better human blood condition. Here we report a rapid (~ 7 hrs) whole blood-based detection method of SARS-CoV-2-specific T cell responses with simple steps that could be adapted to settings of limited resources. This rapidly applicable assay could represent an easily standardizable tool to assess SARS-CoV-2-specific adaptive immunity to monitor T cell responses in vaccine trials, gain insight into what constitutes a protective response, or define the prevalence of SARS-CoV-2 T cell responders population wide.

**METHODS** 

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

Study population The population studied consisted of healthcare workers (HCW, n=31, 29% male) recruited between July and September 2020, from Groot Schuur Hospital in Cape Town, the hardest hit region of the initial COVID-19 epidemic in South Africa (Mendelson et al., 2020). Participants were classified according to i) reporting of COVID-19-associated symptoms, ii) whether a SARS-CoV-2 RNA PCR from a nasal or pharyngeal swab was performed and iii) SARS-CoV-2 PCR results. Based on these criteria, participants were subdivided into three groups: 1) persons with no COVID-19-associated symptoms (n=15); 2) persons who reported symptoms but tested SARS-CoV-2 PCR negative (n = 7); and 3) persons who had COVID-19-associated symptoms and tested SARS-CoV-2 PCR positive (n = 9) (Table 1). In all groups, the exposure to COVID-19 patients was comparable (86.8 to 100%). All participants with PCR confirmed COVID-19 had mild symptoms and did not require hospitalization. Blood samples were obtained a median of 7.3 weeks post-SARS-CoV-2 testing in persons with a negative test results and 4.7 weeks in those with a confirmed positive result (p=0.09). All participants were symptom-free at the time of sampling. In four SARS-CoV-2 PCR positive participants, a second sample was obtained 1 month later. The University of Cape Town's Faculty of Health Sciences Human Research Ethics Committee approved the study (HREC: 207/2020) and written informed consent was obtained from all participants. Measurement of SARS-CoV-2 nucleocapsid-specific IgG in plasma The measurement of SARS-CoV-2 specific antibodies was performed using the Roche Elecsys® Anti-SARS-CoV-2 immunoassay (Roche Diagnostics, Basel, Switzerland). This semiquantitative electro-chemiluminescent immunoassay measures SARS-CoV-2 nucleocapsidspecific IgG. The assay was performed by the South African National Health Laboratory Service

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

(NHLS) and interpreted according to manufacturers' instructions (Roche: V 1.0 2020-05). Results are reported as numeric values in form of a cut-off index (COI; signal sample/cut-off), where a COI  $\leq 1.0$  corresponds to non-reactive plasma and COI  $\geq 1.0$  to reactive plasma. At 14 days post-SARS-CoV-2 PCR confirmation, the sensitivity and specificity of the Elecsys® Anti-SARS-CoV-2 immunoassay is reported as 99.5% (95% CI, 97.0 to 100.0%) and 99.80% (95% CI, 99.69 to 99.88%), respectively (Favresse et al., 2020; Muench et al., 2020; National, 2020). SARS-CoV-2 pseudovirus neutralisation assav Patient plasma was evaluated for SARS-CoV-2 neutralisation activity using a SARS-CoV-2 pseudovirus infection assay. Single-cycle infectious SARS-CoV-2 pseudovirions based on the HIV backbone expressing the SARS-CoV-2 Spike (S) protein and a firefly luciferase reporter were produced in HEK-293TT cells (Buck et al., 2004; Buck et al., 2005) by co-transfection of plasmids pNL4-3.Luc.R-.E- (NIH AIDS Reagent Program (#3418), Germantown, MD, USA) and pcDNA3.3-SARS-CoV-2-spike Δ18 (Rogers et al., 2020). HEK-293TT cell culture supernatants containing the virions were harvested 3 days post transfection and incubated with heat-inactivated patient plasma at 5-fold serial dilutions for 60 min at 37°C. Plasma/pseudovirus mixtures were then used for transfection of HEK-293T cells stably expressing the ACE2 receptor (Mou et al., 2020). Cells were lysed 3 days post infection using the Promega cell culture lysis reagent (Promega Biosciences Inc., San Luis Obispo, CA, USA) and assessed for luciferase activity using a GloMax® Explorer Multimode Microplate Reader (Promega Biosciences) together with the Luciferase assay system (Promega Biosciences). Whole blood-based T cell detection assay Blood was collected in sodium heparin tubes and processed within 3 h of collection. The whole blood-based SARS-CoV-2-specific T cell detection assay was adapted from a previously reported whole blood intracellular cytokine detection assay designed to quantitate Mycobacterium

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

tuberculosis specific T cells in small volumes of blood (Hanekom et al., 2004). However, significant modifications have been made, including a reduced incubation time, the usage of a fixation buffer allowing the simultaneous lysis of red blood cells to streamline processing time, leading to faster acquisition of results (Riou et al., 2020). Here, we adapted this assay to detect SARS-CoV-2 specific T cells using synthetic SARS-CoV-2 PepTivator peptides (Miltenyi Biotec, Surrey, UK), consisting of 15-mer sequences with 11 amino acid overlap covering the immunodominant parts of the spike (S) protein, and the complete sequence of the nucleocapsid (N) and membrane (M) proteins. All peptides were combined in a single pool and used at a final concentration of 1 µg/ml. The workflow of the assay is presented in Figure 1. Briefly, 400 µl whole blood was stimulated with the SARS-CoV-2 S, N and M protein peptide pool at 37°C for 5 hrs in the presence of the co-stimulatory antibodies against CD28 and CD49d (1µg/ml each; BD Biosciences, San Jose, CA, USA) and Brefeldin-A (10µg/ml, Sigma-Aldrich, St Louis, MO, USA). Unstimulated blood was incubated with co-stimulatory antibodies, Brefeldin-A and an equimolar amount of DMSO. Red blood cell lysis and white cell fixation was then performed as a single step using a Transcription Factor Fixation buffer (eBioscience, San Diego, CA, USA) for 20 minutes. At this stage cells were cryopreserved in freezing media (50% foetal bovine serum, 40% RPMI and 10% dimethyl sulfoxide) and stored in liquid nitrogen until batched analysis. Cell staining was performed on cryopreserved cells that were thawed, washed and permeabilised with a Transcription Factor perm/wash buffer (eBioscience). Cells were then stained at room temperature for 30 min with antibodies for CD3 BV650, CD4 BV785, CD8 BV510, CD45RA Alexa 488, CD27 PE-Cy5, CD38 APC, HLA-DR BV605, Ki67 PerCP-cy5.5, PD-1 PE, Granzyme B (GrB) BV421, IFNy BV711, TNFα PE-Cy7 and IL-2 PE/Dazzle 594, as detailed in Supplementary Table 1. Samples were acquired on a BD LSR-II and analysed using FlowJo (v9.9.6, FlowJo LCC, Ashland, OR, USA). A positive response was defined as any cytokine response that was at least twice the background of unstimulated cells. To define the phenotype of

SARS-CoV-2-specific CD4 T cells, a cut-off of 30 events was used. The gating strategy is provided in **Supplementary Figure 1**.

Statistical analyses

Graphical representations were performed in Prism (v8.4.3; GraphPad Software Inc, San Diego, CA, USA) and JMP (v14.0.0; SAS Institute, Cary, NC, USA). Statistical tests were performed in Prism. Non-parametric tests were used for all comparisons. The Kruskal-Wallis test with Dunn's multiple comparison test was used for multiple comparisons and the Mann-Whitney and

Wilcoxon matched pairs test for unmatched and paired samples, respectively.

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

RESULTS Serological assessment of SARS-CoV-2 sensitization. Even though RT-PCR is the most specific technique to detect acute SARS-CoV-2 infection, the positivity rate drops rapidly as soon as 10 days post-symptom onset, particularly in individuals with mild forms of COVID-19 (Liu et al., 2020a; Liu et al., 2020b). Hence, serology assays provide an important complement to RNA testing to identify individuals who have been sensitized by SARS-CoV-2. Thus, to assess potential SARS-CoV-2 sensitization in participants who did not have a SARS-CoV-2 PCR test performed or tested PCR negative, the presence of SARS-CoV-2-specific antibodies (e.g. SARS-CoV-2 nucleocapsid-specific IgG) was measured and a SARS-CoV-2 pseudovirus neutralisation assay was also performed in all participants. While all participants with a positive SARS-CoV-2 PCR test exhibited in vitro anti-SARS-CoV-2 neutralizing activity and 8/9 (88.8%) had detectable SARS-CoV-2 nucleocapsid-specific IgG, none of the participants who tested negative or did not undergo PCR testing were positive for SARS-CoV-2 nucleocapsid-specific IgG (Figure 2A) or displayed robust in vitro anti-SARS-CoV-2 activity (Figure 2B). Overall, these results confirmed that PCR positive participants had been infected with SARS-CoV-2 and mounted an immune response to the virus and suggested that none of the participants who did not have a PCR test performed or tested PCR negative, despite experiencing COVID-19-like symptoms, have been SARS-CoV-2 infected. Magnitude and functional profile of SARS-CoV-2-responding CD4 T cells. Amongst the 31 participants tested, 58% (n=18) had a detectable SARS-CoV-2-specific CD4 T cell response (producing any of the measured cytokines, IFNy, TNFα or IL-2) using the described whole blood assay (Figure 3A). We then defined the magnitude and phenotype of SARS-CoV-2 -specific CD4 responses according to participants' clinical characteristics (Figure 3B&C). All

HCW with self-reported symptoms and a SARS-CoV-2 PCR positive test (n=9) were found to

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

have SARS-CoV-2-specific CD4 T cells (median frequency: 0.47%, IQR: 0.28-0.65) (Figure 3C). Of note, the frequency of SARS-CoV-2 specific CD4 T cells did not associate with the magnitude of SARS-CoV-2 nucleocapsid-specific IgG (p = 0.64, r = -0.18) or plasma neutralizing activity (p = 0.46, r = 0.28) (data not shown). Interestingly, in participants with no detectable SARS-CoV-2 nucleocapsid-specific IgG or neutralizing antibody activity, of those with self-reported symptoms, 3/7 (43%) had detectable SARS-CoV-2-responding CD4 T cells (median of responders: 0.02%, IQR: 0.019-0.03) and 6/15 (40%) of those with no self-reported symptoms had detectable SARS-CoV-2-responding CD4 T cells (median of responders: 0.15%, IQR: 0.05-1.47), suggesting that these responses correspond to SARS-CoV-2 cross-reactive memory CD4 T cells. Next, we defined the polyfunctional profile of SARS-CoV-2-responding CD4 T cells, based on their capacity to co-express IL-2, IFNγ or TNFα (Figure 3D). The overall functional profile of SARS-CoV-2-specific cells in PCR positive participants was distinct from participants with no reported symptoms (p=0.0002). Indeed, the SARS-CoV-2-specific CD4 response in PCR+ participants was characterized by limited expression of IFNy and was enriched in cells coexpressing IL-2 and TNFα. On the contrary, in participants reporting no symptom, most SARSresponding CD4 cells were distributed between triple functional cells (IL-2+IFN $\gamma$ +TNF $\alpha$ +) and cells co-producing IFNγ and TNFα. Overall, in this assay TNFα was the predominant cytokine produced, with its production being significantly higher compared to IL-2 (p = 0.0026) and IFNy (p < 0.0001) (Supplementary Figure 2). Phenotypic assessment of SARS-CoV-2-responding CD4 T cells While the proposed assay can be performed using a limited antibody panel to identify the frequency of SARS-CoV-2-responding T cells, by solely measuring cytokine production, the use of a more extensive antibody panel also permits definition of the phenotypic profile of these cells. To this end, we included additional markers to assess the memory differentiation (CD27,

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

CD45RA), cytotoxic potential (GrB) and activation profile (HLA-DR, CD38, Ki67, PD-1) of SARS-CoV-2-responding CD4 T cells. Figure 4A&B shows that in all individuals with symptoms, SARS-CoV-2-specific CD4 T cells displayed almost exclusively (median: 97.7%) an early differentiated memory phenotype (ED: CD45RA-CD27+). On the contrary, in 4/6 HCW with no symptoms, SARS-CoV-2-specific CD4 T cells exhibited a predominant late differentiated phenotype (LD: CD45RA-CD27-). While the role of cytotoxic CD4 T cells is still unclear, the presence of these cells has been described in several viral infections (Juno et al., 2017). We thus measured GrB expression in SARS-CoV-2-responding CD4 T cells. While GrB was barely detectable in SARS-CoV-2specific CD4 T cells in PCR positive participants, elevated GrB expression was observed in 4 out of 6 participants without symptoms (Figure 4C&D). Moreover, the proportion of ED SARS-CoV-2-responding CD4 T cells inversely associated with GrB expression (p = 0.002, r = -0.71) and the proportion of IFNy and TNF $\alpha$  dual producing cells (p < 0.0001, r = -0.84) (**Figure 4E**). The phenotypic characteristics of GrB expressing SARS-CoV-2-responding CD4 T cells (i.e. highly differentiated and producing IFNγ and TNFα) are in agreement with a recent report describing CMV-specific CD4 CTL T cells (Pachnio et al., 2016). To determine if the overall phenotypic profile of SARS-CoV-2-responding CD4 T cells allowed discrimination of participants based on their clinical characteristics, we performed a hierarchical clustering analysis (Figure 5A) and a principal component analysis (PCA) (Figure 5B), including four parameters (e.g. proportion of IFNy+TNF $\alpha$ +IL2+ and IFNy-TNF $\alpha$ +IL2+ cells, proportion of ED, and GrB expression). Both analyses show that participants who reported no symptoms and were negative for SARS-CoV-2 Abs separated clearly from PCR positive participants. Conversely, PCR and SARS-CoV-2 antibody negative HCWs reporting symptoms could not be separated from PCR positive participants. The loading plot shows that GrB expression and the proportion of triple positive cells were the main drivers permitting the

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

strongest correlation (Figure 6C).

segregation of participants who reported no symptoms and were negative for SARS-CoV-2 Abs (Figure 5C) Lastly, as the expression of activation markers (HLA-DR, CD38, PD-1 or Ki67) on antigenspecific T cells are indicative of active infection (Chen and Wherry, 2020; Mathew et al., 2020), we defined the expression of these markers on SARS-CoV-2-responding CD4 T cells. No significant difference was observed in any of the measured markers amongst the different groups, notwithstanding a few outliers observed in the PCR positive participant group (Figure 6A). Interestingly, regardless of the participants' clinical characteristics, PD-1 expression was highly expressed on SARS-CoV-2-responding CD4 T cells, raising the question of a potential intrinsic dysfunction/exhaustion of coronavirus-specific memory CD4 T cells (Jubel et al., 2020; Wherry and Kurachi, 2015; Wykes and Lewin, 2018). We then defined the relationship between the activation profile of SARS-CoV-2-specific CD4 T cells and time post positive PCR test. Figure 6B shows that in PCR positive participants, the expression of CD38 associated strongly with the time post PCR testing (p < 0.0001, r = -0.91), where CD38 expression decreased sharply in the first 2 to 3 weeks post testing, suggesting a rapid clearance of the pathogen. Similar associations where observed for all tested activation markers, with CD38 expression showing the

### **DISCUSSION**

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

In this proof of concept analysis assessing the use of a simple whole blood assay to measure SARS-CoV-2-specific T cell responses in a small health care worker cohort, we show that SARS-CoV-2-specific CD4 T cells (expressing IFNγ, TNFα or IL-2) were easily detectable in all tested convalescent COVID-19 participants. However, in participants who did not experience any COVID-19-related symptoms or tested SARS-CoV-2 PCR negative (despite reporting symptoms), 9/22 (40.9%) also exhibited a detectable SARS-CoV-2-specific CD4 T cell response. Nevertheless, the median frequency of SARS-CoV-2-specific CD4 T cells in the latter groups was ~ 5-fold lower compared to SARS-CoV-2 PCR positive participants. Importantly, unlike convalescent COVID-19 participants, none of participants without symptoms or who tested PCR negative had detectable SARS-CoV-2 nucleocapsid-specific IgG or displayed robust neutralizing activity. This strongly suggests that in these participants, SARS-CoV-2-responding CD4 T cells may correspond to a pre-existing cross-reactive memory CD4 T cell response. Thus, the sole presence SARS-CoV-2-reactive CD4 T cells does not permit to infer SARS-CoV-2 infection or sensitization. These findings are in line with a number of studies demonstrating the presence of SARS-CoV-2-reactive CD4 T cells in 40 to 60% of SARS-CoV-2-unexposed individuals in different populations around the world (Grifoni et al., 2020; Le Bert et al., 2020; Rydyznski Moderbacher et al., 2020; Sekine et al., 2020). Additionally, it is important to point out that all these studies were performed using PBMC and it is encouraging to find that a whole blood-based assay using limited amount of blood (< 1ml) yields comparable results. Further analyses of the polyfunctional and phenotypical profile of SARS-CoV-2-specific CD4 T cells revealed that regardless of the clinical characteristics of the participants, the most prevalent cytokine detected in response to SARS-CoV-2 peptides was TNFα. These observations are in accordance with other studies pointing out an impairment of SARS-CoV-2 adaptive immune responses, characterized by low level of type I and type II interferon (Blanco-Melo et al.,

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

2020; Sattler et al., 2020). However, it is also possible that the limited IFNy production, we observed in this study, is related to the short stimulation time (e.g. 5hrs) used in the assay. Nevertheless, this suggests that TNFα could be a more reliable target than IFNγ, to detect SARS-CoV-2-specific CD4 T cell responses. Additionally, SARS-CoV-2-responding CD4 T cells in all participants were characterized by elevated of PD-1 expression. Such profiles have been observed in acute SARS-CoV-2 infection and is likely driven by ongoing viral replication (Schub et al., 2020; Sekine et al., 2020; Zheng et al., 2020). However, PD-1 expression on antigen-specific T cells has been shown to decrease upon pathogen clearance (Barber et al., 2006; Sester et al., 2008). Thus, elevated PD-1 expression in COVID-19 convalescent persons and uninfected responders could reflect an intrinsic state of functional exhaustion of SARS-CoV-2-reactive memory CD4 T cells. Lastly, SARS-CoV-2-responding CD4 T cells were qualitatively different between convalescent COVID-19 participants and participants who did not experience COVID-19associated symptoms. In the former group, SARS-CoV-2-specific CD4 T cells displayed almost exclusively an early differentiated memory phenotype; while in the latter group, SARS-CoV-2responsive CD4 T cells exhibited a late differentiated memory phenotype and were enriched in GrB. Differences in the attributes of SARS-CoV-2-reactive T cells distinguishing recent SARS-CoV-2 infection from pre-existing immunity have been recently reported: strong ex vivo Elispot responses and enhanced proliferation capacity were frequently observed in confirmed COVID-19 patients but rare in pre-pandemic or unexposed seronegative persons (Ogbe et al., 2020). This is consistent with the phenotypic features we observed in our study. It remains to be determined whether the presence of pre-existing cross-reactive memory T cells offers any protection against SARS-CoV-2. Although our results rely on a small number of participants and need to be confirmed in larger cohorts, this study suggests that a whole blood assay could represent a valuable tool to assess SARS-CoV-2-specific adaptive immunity. The whole blood assay described here is rapid

and scalable for varying complexities depending on laboratory resources and questions to be addressed. It can be adapted to a simple 4-colour flow cytometry assay to monitor the frequency of T cell responses in epidemiological studies or vaccine trials. Alternatively, it can also be used to characterize in more depth the specific attributes of SARS-CoV-2-specific T cells, as shown here, to aid deciphering cellular features that may associate with immune correlates of protection. Finally, as this standardizable assay requires a limited volume of blood, it can be easily used in COVID-19 paediatric cases.

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

**Acknowledgment:** The authors thank all the participants. **Funding sources**: This work was supported by Wellcome [grant number: 104803 and 203135] and Crick idea to innovation (i2i) scheme in partnership with the Rosetrees Trust [grant number: 2020-0009]. CR is supported by the European and Developing Countries Clinical Trials Partnership EDCTP2 programme supported by the European Union (EU)'s Horizon 2020 programme [grant number: Training and Mobility Action TMA2017SF-1951-TB-SPEC to CR] and the National Institutes of Health (NIH) [grant number: R21AI148027 to CR]. GS is supported by the European and Developing Countries Clinical Trials Partnership EDCTP2 programme [grant number: Training and Mobility Action TMA2018SF-2446 to GS]. RJW and KAW receive support from the Francis Crick institute, which is funded by the UK Medical Research Council UKRI, Cancer Research UK and Wellcome [grant number: FC0010218]. Author contributions: CR, KAW and RJW designed the study. CR performed the whole blood assay and flow cytometry experiments and analysed and interpreted the data. GS performed the neutralizing assay experiments. EdB, RTG and CS recruited the study participants. KAW, HM and EL provided critical reagents. CR and KAW wrote the manuscript with all authors contributing to providing critical feedback.

**Conflict of interest:** The authors declare no conflict of interest.

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

FIGURE LEGENDS

Figure 1: Schematic showing methodology and workflow of the whole blood assay for the detection of SARS-CoV-2-specific adaptive immune responses. Step 1: 400 µl of heparinized whole blood is incubated for 5 hours in the presence of a SARS-CoV-2-specific peptide pool in the presence of co-stimulatory antibodies (i.e. CD28 and CD49d) and Brefeldin-A. Step 2: Cells are incubated for 20 min in the presence of a transcription factor fixation buffer, leading to the simultaneous lysis of red blood cells and cell fixation. Step 3: Cells are stained for 30 min with an optimized panel of fluorophore labelled antibodies. Step 4: Samples are acquired on a flow cytometer. Control samples are processed with a similar workflow in the absence of SARS-CoV-2-specific peptide pool. Figure 2: SARS-CoV-2 serological assessment. A- Quantification of SARS-CoV-2 Nucleocapsid-specific antibodies using the Elecsvs® Roche assay expressed as a cut-off index (signal sample/cut-off). Participants were grouped according to their clinical characteristics (Blue: no symptoms, no SARS-CoV-2 PCR performed; Orange: self-reported symptoms, SARS-CoV-2 PCR negative; and Red: self-reported symptoms, SARS-CoV-2 PCR positive). Bars represent the medians. The dotted line indicates the manufacturer's cut-off value for positivity. Statistical comparisons were performed using a Mann-Whitney T- test. **B-** SARS-CoV-2 pseudovirus neutralization activity. SARS-CoV-2 pseudovirions pre-incubated with serially diluted patient plasma were used to infect ACE2-expressing HEK-293T cells. Luciferase activity as a measure for infection was assessed 3 days post-infection, and results are expressed as infection compared to control (untreated virions, grey shaded area) which was set 100%. Figure 3: Magnitude and functional profile of SARS-CoV-2-specific CD4 T cells. A-Proportion of participants exhibiting a detectable SARS-CoV-2-specific CD4 T cell response. **B-**

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

Representative examples of TNFα and IFNy production in CD4 T cells in response to SARS-CoV-2 peptide pool. NS: no stimulation. C- Magnitude of SARS-CoV-2-specific CD4 T cell response (expressed as a percentage of total CD4 T cells) in participants grouped according to their clinical characteristics (Blue: no symptoms, no SARS-CoV-2 PCR performed; Orange: selfreported symptoms, SARS-CoV-2 PCR negative; and Red: self-reported symptoms, SARS-CoV-2 PCR positive). The number of participants and % of responders in each group is presented at the bottom of the graph. Statistical comparisons were performed using the Kruskal-Wallis test. **D**-Polyfunctional profile of SARS-CoV-2-specific CD4 T cells in each group. The x-axis displays the composition of each combination which is denoted with a dot for the presence of IL-2, IFNy and TNFα. The medians (black bar) are shown. Each combination is color-coded, and data are summarized in the pie charts, where each pie slice represents the median contribution of each combination to the total SARS-CoV-2 response. The arcs identify the contribution of TNFα (light grey), IL-2 (grey) and IFNy (black) to SARS-CoV-2 response. The Wilcoxon Rank Sum Test was used to compare response patterns between groups. Statistical differences between pie charts were defined using a permutation test. Figure 4: Memory differentiation profile and Granzyme B (GrB) expression in SARS-CoV-2-specific CD4 T cells. A- Representative examples of the memory differentiation profile of SARS-CoV-2-specific CD4 T cells based on the expression of CD45RA and CD27. The flow plot on the right shows the distribution of Naïve (CD45RA+CD27+), Early differentiated (ED: CD45RA-CD27+), Late differentiated (LD: CD45RA-CD27-) and Effector (Eff: CD45RA+CD27-) in total CD4 T cells. **B-** Summary graph of the proportion of ED and LD in SARS-CoV-2-specific CD4 T cells in each group (Blue: no symptoms, no SARS-CoV-2 PCR performed; Orange: self-reported symptoms, SARS-CoV-2 PCR negative and Red: self-reported symptoms, SARS-CoV-2 PCR positive). Statistical comparisons were performed using the Kruskal-Wallis test. C- Representative examples of GrB expression in total and SARS-CoV-2-

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

specific CD4 T cells. **D-** Summary graph of GrB expression in SARS-CoV-2-specific CD4 T cells in each group. Statistical comparisons were performed using the Kruskal-Wallis test. E-Relationship between the proportion of ED within SARS-CoV-2-specific CD4 T cells and GrB expression or the proportion of IFNy+TNF $\alpha$ +IL2- SARS-CoV-2-specific CD4 T cells. Correlations were tested by a two-tailed non-parametric Spearman rank test. Figure 5: Phenotypic signature of SARS-CoV-2-specific IFNγ+ CD4+ T cells according to clinical characteristics. A- Non-supervised two-way hierarchical cluster analysis (HCA, Ward method) using three phenotypic parameters (i.e. GrB expression and the proportion of ED and IFNy+TNFα+IL2-) from SARS-CoV-2-specific CD4 T cells. Each column represents a participant and is color-coded according to their clinical characteristics indicated by a dot at the top of the dendrogram (Blue: no symptoms, no SARS-CoV-2 PCR performed; Orange: selfreported symptoms, SARS-CoV-2 PCR negative; and Red: self-reported symptoms, SARS-CoV-2 PCR positive). Participants with a positive SARS-CoV-2 serology test are indicated by a black box and a white box identifies SARS-CoV-2 antibody-negative subjects. Data are depicted as a heatmap coloured from minimum to maximum values for each parameter. B- Principal component analysis on correlations, derived from the three studied parameters. Each dot represents a participant. The two axes represent principal components 1 (PC1) and 2 (PC2). Their contribution to the total data variance is shown as a percentage. C- Loading plot showing how each parameter influences PC1 and PC2 values. Figure 6: Activation profile of SARS-CoV-2-specific CD4 T cells. A- CD38, HLA-DR, Ki67 and PD-1 expression in SARS-CoV-2-specific CD4 T cells in each group (Blue: no symptoms, no SARS-CoV-2 PCR performed; Orange: self-reported symptoms, SARS-CoV-2 PCR negative and Red: self-reported symptoms, SARS-CoV-2 PCR positive). No significant differences were observed between groups for any markers, using the Kruskal-Wallis test. **B-** Association between

CD38 expression in SARS-CoV-2-specific CD4 T cells and the time post SARS-CoV-2 PCR positive test (weeks). Each symbol represents a participant (n=9). Dotted red lines identify participant with longitudinal samples. Correlations were tested by a two-tailed non-parametric Spearman rank test. **C-** Comparison of the correlation between the time post SARS-CoV-2 PCR positive test (weeks) and the expression of different activation profile markers, ranked according to the strength of the association. Spearman correlation r values are plotted on the x-axis and corresponding *P*-values are shown within each bar.

#### REFERENCES

432

433

439

440 441

442

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470 471

- 434 Altmann, D.M., and R.J. Boyton. 2020. SARS-CoV-2 T cell immunity: Specificity, function, 435 durability, and role in protection. Sci Immunol 5. DOI: 10.1126/sciimmunol.abd6160:
- 436 Barber, D.L., E.J. Wherry, D. Masopust, B. Zhu, J.P. Allison, A.H. Sharpe, G.J. Freeman, and R. 437 Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. 438 Nature 439:682-687.
  - Blanco-Melo, D., B.E. Nilsson-Payant, W.C. Liu, S. Uhl, D. Hoagland, R. Moller, T.X. Jordan, K. Oishi, M. Panis, D. Sachs, T.T. Wang, R.E. Schwartz, J.K. Lim, R.A. Albrecht, and B.R. tenOever. 2020. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181:1036-1045 e1039.
- 443 Braun, J., L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, S. Hippenstiel, M. Dingeldey, 444 B. Kruse, F. Fauchere, E. Baysal, M. Mangold, L. Henze, R. Lauster, M.A. Mall, K. 445 Bever, J. Rohmel, S. Voigt, J. Schmitz, S. Miltenvi, I. Demuth, M.A. Muller, A. Hocke, 446 M. Witzenrath, N. Suttorp, F. Kern, U. Reimer, H. Wenschuh, C. Drosten, V.M. Corman, 447 C. Giesecke-Thiel, L.E. Sander, and A. Thiel. 2020. SARS-CoV-2-reactive T cells in 448 healthy donors and patients with COVID-19. Nature Doi: 10.1038/s41586-020-2598-9:
  - Buck, C.B., D.V. Pastrana, D.R. Lowy, and J.T. Schiller. 2004. Efficient intracellular assembly of papillomaviral vectors. J Virol 78:751-757.
  - Buck, C.B., D.V. Pastrana, D.R. Lowy, and J.T. Schiller. 2005. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 119:445-462.
  - Canete, P.F., and C.G. Vinuesa. 2020. COVID-19 makes B cells forget, but T cells remember. Cell 183:13-15.
  - Chen, Z., and E.J. Wherry. 2020. T cell responses in patients with COVID-19. Nat Rev Immunol 20:529-536.
  - Cox, R.J., and K.A. Brokstad. 2020. Not just antibodies: B cells and T cells mediate immunity to COVID-19. *Nat Rev Immunol* 20:581-582.
    - Favresse, J., C. Eucher, M. Elsen, M. Tre-Hardy, J.M. Dogne, and J. Douxfils. 2020. Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. Clin Chem 66:1104-1106.
    - Grifoni, A., D. Weiskopf, S.I. Ramirez, J. Mateus, J.M. Dan, C.R. Moderbacher, S.A. Rawlings, A. Sutherland, L. Premkumar, R.S. Jadi, D. Marrama, A.M. de Silva, A. Frazier, A.F. Carlin, J.A. Greenbaum, B. Peters, F. Krammer, D.M. Smith, S. Crotty, and A. Sette. 2020. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181:1489-1501 e1415.
    - Hanekom, W.A., J. Hughes, M. Mavinkurve, M. Mendillo, M. Watkins, H. Gamieldien, S.J. Gelderbloem, M. Sidibana, N. Mansoor, V. Davids, R.A. Murray, A. Hawkridge, P.A. Haslett, S. Ress, G.D. Hussey, and G. Kaplan. 2004. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J Immunol Methods 291:185-195.
- Jubel, J.M., Z.R. Barbati, C. Burger, D.C. Wirtz, and F.A. Schildberg. 2020. The role of PD-1 in 472 473 acute and chronic infection. Front Immunol 11:487.
- 474 Juno, J.A., D. van Bockel, S.J. Kent, A.D. Kelleher, J.J. Zaunders, and C.M. Munier. 2017. 475 Cytotoxic CD4 T cells - Friend or foe during viral infection? Front Immunol 8:19.
- 476 Le Bert, N., A.T. Tan, K. Kunasegaran, C.Y.L. Tham, M. Hafezi, A. Chia, M.H.Y. Chng, M. Lin, N. Tan, M. Linster, W.N. Chia, M.I. Chen, L.F. Wang, E.E. Ooi, S. Kalimuddin, P.A. 477
- 478 Tambyah, J.G. Low, Y.J. Tan, and A. Bertoletti. 2020. SARS-CoV-2-specific T cell
- 479 immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584:457-480 462.

- 481 Lipsitch, M., Y.H. Grad, A. Sette, and S. Crotty. 2020. Cross-reactive memory T cells and herd 482 immunity to SARS-CoV-2. Nat Rev Immunol 20:709-713.
- 483 Liu, L., W. Liu, Y. Zheng, X. Jiang, G. Kou, J. Ding, Q. Wang, Q. Huang, Y. Ding, W. Ni, W. 484 Wu, S. Tang, L. Tan, Z. Hu, W. Xu, Y. Zhang, B. Zhang, Z. Tang, X. Zhang, H. Li, Z. 485 Rao, H. Jiang, X. Ren, S. Wang, and S. Zheng. 2020a. A preliminary study on serological 486 assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 487 admitted hospital patients. Microbes Infect 22:206-211.
- 488 Liu, Y., L.M. Yan, L. Wan, T.X. Xiang, A. Le, J.M. Liu, M. Peiris, L.L.M. Poon, and W. Zhang. 489 2020b. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 20:656-490 657.
- 491 Margolin, E., W.A. Burgers, E.D. Sturrock, M. Mendelson, R. Chapman, N. Douglass, A.L. 492 Williamson, and E.P. Rybicki. 2020. Prospects for SARS-CoV-2 diagnostics, therapeutics 493 and vaccines in Africa. Nat Rev Microbiol DOI: 10.1038/s41579-020-00441-3:
- 494 Mathew, D., J.R. Giles, A.E. Baxter, D.A. Oldridge, A.R. Greenplate, J.E. Wu, C. Alanio, L. 495 Kuri-Cervantes, M.B. Pampena, K. D'Andrea, S. Manne, Z. Chen, Y.J. Huang, J.P. Reilly, 496 A.R. Weisman, C.A.G. Ittner, O. Kuthuru, J. Dougherty, K. Nzingha, N. Han, J. Kim, A. 497 Pattekar, E.C. Goodwin, E.M. Anderson, M.E. Weirick, S. Gouma, C.P. Arevalo, M.J. 498 Bolton, F. Chen, S.F. Lacey, H. Ramage, S. Cherry, S.E. Hensley, S.A. Apostolidis, A.C. 499 Huang, L.A. Vella, U.P.C.P. Unit, M.R. Betts, N.J. Meyer, and E.J. Wherry. 2020. Deep 500 immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic 501 implications. Science 369. DOI: 10.1126/science.abc8511:

503

504

505

507

508

- Mendelson, M., L. Boloko, A. Boutall, L. Cairncross, G. Calligaro, C. Coccia, J.A. Dave, M. de Villiers, S. Dlamini, P. Frankenfeld, P. Gina, M.V. Gule, J. Hoare, R. Hofmeyr, M. Hsiao, I. Joubert, T. Kahn, R. Krause, A. Kroopman, D. Levin, D. Maughan, S. Mazondwa, G. Meintjes, R. Nordien, N. Ntusi, N. Papavarnavas, J. Peter, H. Pickard, P. Raubenheimer, 506 Q. Said-Hartley, P. Singh, S. Wasserman, and o.b.o.t.G.S.H.C.-R. Team. 2020. Clinical management of COVID-19: Experiences of the COVID-19 epidemic from Groote Schuur Hospital, Cape Town, South Africa. South African Medical Journal 110:973-981.
- 509 Mou, H., B.D. Quinlan, H. Peng, Y. Guo, S. Peng, L. Zhang, M.E. Davis-Gardner, M.R. Gardner, 510 G. Crynen, Z.X. Voo, C.C. Bailey, M.D. Alpert, C. Rader, H. Choe, and M. Farzan. 2020. 511 Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-512 CoV-2. BioRxiv DOI: 10.1101/2020.06.29.178459:
- 513 Muench, P., S. Jochum, V. Wenderoth, B. Ofenloch-Haehnle, M. Hombach, M. Strobl, H. 514 Sadlowski, C. Sachse, G. Torriani, I. Eckerle, and A. Riedel. 2020. Development and 515 validation of the Elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for 516 determining past exposure to SARS-CoV-2. J Clin Microbiol 58. DOI: 517 10.1128/JCM.01694-20:
- 518 National, S.-C.-S.A.E.G. 2020. Performance characteristics of five immunoassavs for SARS-519 CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. DOI: 10.1016/S1473-520 3099(20)30634-4:
- 521 Ogbe, A., B. Kronsteiner, D.T. Donal T. Skelly, M. Pace, and A. Brown. 2020. T cell assays 522 differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral 523 responses. MedRxiv DOI: 10.1101/2020.1109.1128.20202929.
- 524 Pachnio, A., M. Ciaurriz, J. Begum, N. Lal, J. Zuo, A. Beggs, and P. Moss. 2016. 525 Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-526 specific CD4+ T cells targeted to vascular endothelium. *PLoS Pathog* 12:e1005832.
- 527 Quinti, I., V. Lougaris, C. Milito, F. Cinetto, A. Pecoraro, I. Mezzaroma, C.M. Mastroianni, O. 528 Turriziani, M.P. Bondioni, M. Filippini, A. Soresina, G. Spadaro, C. Agostini, R. Carsetti, 529 and A. Plebani. 2020. A possible role for B cells in COVID-19? Lesson from patients 530 with agammaglobulinemia. J Allergy Clin Immunol 146:211-213 e214.
- 531 Riou, C., E. Du Bruyn, S. Ruzive, R.T. Goliath, C.S. Lindestam Arlehamn, A. Sette, A. Sher, 532 D.L. Barber, and R.J. Wilkinson. 2020. Disease extent and anti-tubercular treatment

- 533 response correlates with Mycobacterium tuberculosis-specific CD4 T-cell phenotype 534 regardless of HIV-1 status. Clin Transl Immunology 9:e1176.
- 535 Rogers, T.F., F. Zhao, D. Huang, N. Beutler, A. Burns, W.T. He, O. Limbo, C. Smith, G. Song, J. 536 Woehl, L. Yang, R.K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L. Peng, S. 537 Ramirez, J. Ricketts, M.J. Ricciardi, S.A. Rawlings, N.C. Wu, M. Yuan, D.M. Smith, D. 538 Nemazee, J.R. Teijaro, J.E. Voss, I.A. Wilson, R. Andrabi, B. Briney, E. Landais, D. Sok, 539 J.G. Jardine, and D.R. Burton. 2020. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369:956-963. 540
- 541 Rydyznski Moderbacher, C., S.I. Ramirez, J.M. Dan, A. Grifoni, K.M. Hastie, D. Weiskopf, S. 542 Belanger, R.K. Abbott, C. Kim, J. Choi, Y. Kato, E.G. Crotty, C. Kim, S.A. Rawlings, J. 543 Mateus, L.P.V. Tse, A. Frazier, R. Baric, B. Peters, J. Greenbaum, E. Ollmann Saphire, 544 D.M. Smith, A. Sette, and S. Crotty. 2020. Antigen-specific adaptive immunity to SARS-545 CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. DOI: 546 10.1016/j.cell.2020.09.038:
- 547 Sattler, A., S. Angermair, H. Stockmann, K.M. Heim, D. Khadzhynov, S. Treskatsch, F. Halleck, 548 M.E. Kreis, and K. Kotsch. 2020. SARS-CoV-2 specific T-cell responses and correlations 549 with COVID-19 patient predisposition. J Clin Invest. DOI: 10.1172/JCI140965:
- 550 Schub, D., V. Klemis, S. Schneitler, J. Mihm, P.M. Lepper, H. Wilkens, R. Bals, H. Eichler, B.C. 551 Gartner, S.L. Becker, U. Sester, M. Sester, and T. Schmidt. 2020. High levels of SARS-552 CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. JCI 553 Insight 5:e142167.
- 554 Sekine, T., A. Perez-Potti, O. Rivera-Ballesteros, K. Stralin, J.B. Gorin, A. Olsson, S. Llewellyn-555 Lacey, H. Kamal, G. Bogdanovic, S. Muschiol, D.J. Wullimann, T. Kammann, J. Emgard, T. Parrot, E. Folkesson, C.-S.G. Karolinska, O. Rooyackers, L.I. Eriksson, J.I. Henter, A. 556 557 Sonnerborg, T. Allander, J. Albert, M. Nielsen, J. Klingstrom, S. Gredmark-Russ, N.K. 558 Bjorkstrom, J.K. Sandberg, D.A. Price, H.G. Ljunggren, S. Aleman, and M. Buggert. 559 2020. Robust T cell immunity in convalescent individuals with asymptomatic or mild 560 COVID-19. Cell 183:158-168 e114.
  - Sester, U., D. Presser, J. Dirks, B.C. Gartner, H. Kohler, and M. Sester. 2008. PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 8:1486-1497.
  - Sette, A., and S. Crotty. 2020. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol 20:457-458.

562

563

564

565

574

- 566 Wherry, E.J., and M. Kurachi. 2015. Molecular and cellular insights into T cell exhaustion. *Nat* 567 Rev Immunol 15:486-499.
- 568 Wykes, M.N., and S.R. Lewin. 2018. Immune checkpoint blockade in infectious diseases. *Nat* 569 Rev Immunol 18:91-104.
- 570 Zheng, H.Y., M. Zhang, C.X. Yang, N. Zhang, X.C. Wang, X.P. Yang, X.Q. Dong, and Y.T. 571 Zheng. 2020. Elevated exhaustion levels and reduced functional diversity of T cells in 572 peripheral blood may predict severe progression in COVID-19 patients. Cell Mol 573 Immunol 17:541-543.

	Hea			
n	15	7	9	<i>P</i> -value
Self-reported symptoms	No	Yes	Yes	-
Tested for COVID	No	Yes	Yes	-
Positive SARS-CoV-2 PCR	na	No	Yes	-
Positive SARS-CoV-2 N-spe IgG (%) <sup>a</sup>	0%	0%	<b>88.9%</b> (8/9)	-
Presence of SARS nAbs (%)b	0%	0%	100%	-
Contact with COVID patients (%)	86.6%	100%	88.9%	ns
Time post PCR test (weeks) <sup>c</sup>	na	<b>7.3</b> [6.3-8.4]	<b>4.7</b> [2.6-7.2]	0.09

## **Table 1: Clinical characteristics of study participants**

<sup>&</sup>lt;sup>a</sup> Measured using the Elecsys® Roche system

<sup>&</sup>lt;sup>b</sup> Measured using a SARS-CoV-2 pseudovirus neutralisation assay

<sup>&</sup>lt;sup>c</sup> Median and Interquartile range (IQR)

Figure 1









Figure 2













Markers	Fluorochrome	Clone	Company	Cat. Number	Role	
CD3	BV650	OKT3	BioLegend	317323	Lineage	
CD4	BV785	OKT4	BioLegend	317428		
CD8	BV510	RPA-T8	BioLegend	301048		
CD45RA	Alexa 488	HI100	BioLegend	304114	Memory differentiation	
CD27	PE-Cy5	1A4CD27	Beckman	6607107		
CD38	APC	HIT2	BD Bioscience	555462	Activation	
HLA-DR	BV605	L243	BioLegend	307640		
Ki67	PerCP-Cy5.5	B56	BD Bioscience	561284		
PD-1	PE	EH12.2H7	BioLegend	329906		
GrB	BV421	GB11	BD Bioscience	563388	Cytotoxic potential	
IFNy	BV711	4S.B3	BioLegend	502540		
TNFα	PE-Cy7	MAB11	BioLegend	502930	Functions	
IL-2	PE/Dazzle™ 594	MQ1-17H12	BioLegend	500344		


**Supp table 1:** Description of the antibody panel used in the study.



# C- Phenotype of SARS-CoV-2-specific CD4 T cells



**Supp Figure 1:** Gating strategy used to identify SARS-CoV-2 specific CD4 T cells and defined their phenotypic characteristics. **A-** Cell lineage. **B-** Phenotyping of total CD4 T cell and cytokine production in response to SARS-CoV-2 peptides. **C-** Phenotype of SARS-CoV-2 responding CD4 T cells in one participant with no symptom (left) and one COVID-19 confirmed participant (right). SARS-CoV-2-specific CD4 T cells (expressing any measured cytokine) are depicted in red.



Supp Figure 2: Comparison of magnitude of SARS-CoV-2-specific CD4 T cell response expressing TNFα, IL-2 or IFNγ in participants exhibiting a detectable response to SARS-CoV-2 peptide pool. Each dot represent a participant and is color-coded according to clinical characteristics (Blue represents no symptoms, no SARS-CoV-2 PCR performed; Orange: self-reported symptoms, SARS-CoV-2 PCR negative and Red: self-reported symptoms, SARS-CoV-2 PCR positive). Black bars indicate medians. Statistical comparisons were performed using a nonparametric paired Friedman test.